2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-15790H
    (S)-Elobixibat 439087-68-0 98.75%
    (S)-Elobixibat is the S enantiomer of Elobixibat (HY-15790). (S)-Elobixibat is an orally effective Apical Sodium-Dependent Bile (IBAT) inhibitor. (S)-Elobixibat decreases LDL cholesterol, increases serum GLP-1, promotes colon motility, and has the potential to study metabolic syndrome. (S)-Elobixibat can be used to study constipation, dyslipidemia, non-alcoholic hepatitis, and liver tumors.
    (S)-Elobixibat
  • HY-158337
    Nesosteine 84210-62-8
    Nesosteine (CO-1177) is a bronchitis inhibitor that improves the rheology and production of airway bronchial mucus in rabbits. Nesosteine significantly reduced the viscosity of airway bronchial mucus in animals with sulfuric acid nebulized bronchitis and increased mucus production in healthy animals. Nesosteine is more active than mucus-regulating drugs such as Sobrerol, N-acetylcysteine, bromhexine, ambroxol, S-carboxymethylcysteine, and mercaptoalanine. Nesosteine also reduced the content of total proteins in airway bronchial mucus, such as albumin, α1, α2, β, and γ mucins.
    Nesosteine
  • HY-158990
    GE1111 2883669-12-1
    GE1111 is a MRGPRX2 antagonist (IC50 = 9.4 μM). GE1111 inhibits MRGPRX2/MRGPRB2-mediated mast cell activation. GE1111 reduces the expressions of TSLP, IL-13, MCP-1, TNF-α, IL-1β and periostin, maintains the expression levels of claudin 1 and involucrin, restores the phagocytic activity of macrophages, and attenuates the activation of STIM1 and phosphorylated AKT. GE1111 exerts anti-inflammatory and anti-allergic effects in multiple animal models. GE1111 is applicable to the research related to rosacea, atopic dermatitis and ulcerative colitis.
    GE1111
  • HY-159632
    PAR4 antagonist 6 99.35%
    PAR4 antagonist 6 (Compound 12) is a PAR4 antagonist, with IC50 values of 134 and 401 nM for hPAR4 (PAC1) and mPAR4 (PAC1), respectively.
    PAR4 antagonist 6
  • HY-159745
    Liposomal adjuvant (M107)
    Liposomal adjuvant (M107) is mainly composed of phospholipids and prepared with highly purified immunostimulatory substances, with a pH value of 5-7. This adjuvant is safe, non-toxic, and metabolizable. It can induce strong Th1-mediated cellular immunity. This adjuvant is suitable for various pet vaccines, such as feline panleukopenia, rhinotracheitis, calicivirus (FRC), canine distemper, adenovirus, parvovirus, parainfluenza (DAPP), and others.
    Liposomal adjuvant (M107)
  • HY-159746
    Carbomer adjuvant (HS801)
    Carbomer adjuvant (HS801) is an adjuvant composed of carbomer and cationic polymers. This adjuvant is safe, non-toxic, and metabolizable. It can enhance the immune response, increase the antibody titer of each antigen component of the vaccine after immunization, and reduce the number of immunizations required. It is suitable for various veterinary vaccines. It is recommended for use in porcine circovirus, mycoplasma hyopneumoniae, and haemophilus parasuis.
    Carbomer adjuvant (HS801)
  • HY-15985A
    CTX-0294885 hydrochloride 2319590-02-6 99.73%
    CTX-0294885 hydrochloride is a broad spectrum kinase inhibitor that can capture 235 kinases from MDA-MB-231 cells, and can capture all members of the AKT family. CTX-0294885 hydrochloride is a powerful reagent for analysis of kinome signaling networks that can be used for the research of diseases like inflammation, diabetes, and cancer.
    CTX-0294885 hydrochloride
  • HY-159944
    PPARγ agonist 14 6951-57-1 98.0%
    PPARγ agonist 14 (compound 3) is a PPARy agonist (EC50=2.4 μM) with anti-diabetic activity. PPARγ agonist 14 can improve intracellular glucose uptake, promote insulin release, and lower blood sugar. In addition, PPARγ agonist 14 also improves mitochondrial function, reduces oxidative stress, and inhibits inflammatory factors. PPARγ agonist 14 can be used in the study of neurodegenerative diseases, neuroinflammatory diseases, and other diseases.
    PPARγ agonist 14
  • HY-159978
    EOS789 1628848-73-6 99.14%
    EOS789 is an orally active sodium-dependent phosphate transporter inhibitor, with IC50 values of 6.8, 1.5, and 1.7 μM against human NaPi-IIb, PiT-1, PiT-2, respectively; and IC50 values of 3.9, 1.9, and 1.7 μM against rat NaPi-IIb, PiT-1, PiT-2, respectively. EOS789 inhibits intestinal phosphate absorption, increases fecal phosphate excretion, reduces urinary phosphate excretion, and decreases the levels of serum phosphate, FGF23, and adult parathyroid hormone. EOS789 ameliorates ectopic thoracic aortic calcification, renal injury and hyperphosphatemia, and inhibits the expression of fibrosis markers. EOS789 can be used for the research of hyperphosphatemia and chronic kidney disease-mineral and bone disorder (CKD-MBD).
    EOS789
  • HY-160906
    Glutathione trisulfide 32607-79-7
    Glutathione trisulfide (GSSSG) is a potent neuroprotective agent with anti-inflammatory activity. Glutathione trisulfide prevents the LPS (HY-D1056)-induced inflammatory gene expression in retinal pigment epithelial cells, which is mediated through hyperactivation of ERK signaling, independent of the NRF2/HMOX1 pathway. Glutathione trisulfide can be used for neurodegenerative diseases and ischemic spinal cord injury (SCI) research.
    Glutathione trisulfide
  • HY-160966
    PROTAC BTK Degrader-10 2988804-46-0 99.24%
    PROTAC BTK Degrader-10 (Example 1P) is a PROTAC degrader for BTK. PROTAC BTK Degrader-10 can be used for research of chronic lymphocytic leukemia (CLL).
    PROTAC BTK Degrader-10
  • HY-161057
    HG-7-86-01 1258391-14-8 98.41%
    HG-7-86-01 (Compound 26) is type II tyrosine kinase inhibitor. HG-7-86-01 has anti-proliferative activity.
    HG-7-86-01
  • HY-161254
    ATPase-IN-3 1134203-12-5 99.89%
    ATPase-IN-3 (compound 6) is a ATPase inhibitor. ATPase-IN-3 has Gastroprotective effect in ethanol-induced gastric ulcers by contribution of anti-apoptotic (BCL-2) and tumor suppressor (P53) proteins.
    ATPase-IN-3
  • HY-161389
    SP-alkyne 98%
    SP-alkyne (compound 8) suppresses IL-2 production and AP-1 and NFAT reporters.
    SP-alkyne
  • HY-161541
    Estradiol/BSA
    Estradiol/BSA is the antigen-adjuvant conjugate formed by the coupling of Estradiol (HY-B0141) with Bovine Serum Albumin (BSA). By coupling the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
    Estradiol/BSA
  • HY-161560
    Tacrolimus/BSA
    Tacrolimus/BSA is the antigen-adjuvant conjugate formed by the conjugation of Tacrolimus (HY-13756) with Bovine Serum Albumin (BSA). By conjugating the antigen with a protein adjuvant, it can enhance the production of antigen-specific antibodies in vaccine models. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
    Tacrolimus/BSA
  • HY-161564
    T4/OVA
    T4/OVA is a conjugate of T4 peptide (thyroxine T4) and ovalbumin. T4/OVA is a altered peptide, which can be used to stimulate OT-I CD8+ T cells.
    T4/OVA
  • HY-161627
    Anemoside A3-methyl 6-aminohexanoate 2919975-48-5 98.62%
    Anemoside A3-methyl 6-aminohexanoate is an orally effective pyruvate carboxylase (PC) inhibitor with a Kd value of 10.1 μM against human PC. Anemoside A3-methyl 6-aminohexanoate exerts its function through the PC/NF-κB/NLRP3 inflammasome axis. Anemoside A3-methyl 6-aminohexanoate significantly alleviates symptoms of DSS (HY-116282C)-induced colitis in mice. Anemoside A3-methyl 6-aminohexanoate can be used in colitis-related research.
    Anemoside A3-methyl 6-aminohexanoate
  • HY-161781
    HVH-2930 3034605-72-3
    HVH-2930 is a HSP90 C-terminal domain inhibitor with high oral bioavailability. HVH-2930 downregulates HSP90 client proteins, inhibits the HER2 signaling pathway, induces apoptosis, and suppresses the proliferation of breast cancer cells. HVH-2930 inhibits the proliferation of tumors sensitive or resistant to Trastuzumab (HY-P9907). HVH-2930 is applicable to relevant research on breast cancer.
    HVH-2930
  • HY-162267
    LPAR1 antagonist 1 3032275-33-2 98.85%
    LPAR1 antagonist 1 (compound 18) is a potent, oral active and selective LPAR1 antagonist with the IC50 of 3.3 nM. LPAR1 antagonist 1 can be used for study of fibrosis.
    LPAR1 antagonist 1
Cat. No. Product Name / Synonyms Application Reactivity